Related Experiment Videos
Hyperthermic pleural perfusion with cisplatin: early clinical experience
A Yellin1, D A Simansky, M Paley
1Department of Thoracic Surgery, Sheba Medical Center, Tel Hashomer, Israel. ayellin@sheba.health.gov.il
Cancer
|October 12, 2001
Summary
This study found that intraoperative hyperthermic pleural perfusion (HPP) with cisplatin is a safe and feasible treatment for pleural malignancies, offering excellent local control and improved survival rates for patients.
Area of Science:
- Oncology
- Thoracic Surgery
- Medical Physics
Background:
- Optimal treatment for pleural tumors remains undetermined.
- Previous research focused on systemic or local modalities separately.
- Multimodality treatment combining surgery, chemotherapy, and hyperthermia requires investigation.
Purpose of the Study:
- To assess the feasibility of intraoperative hyperthermic pleural perfusion (HPP) with cisplatin.
- To evaluate the toxicity and early outcomes of this combined approach.
- To determine the efficacy in treating pleural malignancies.
Main Methods:
- 26 patients with pleural malignancies received intraoperative HPP with cisplatin.
- Perfusion involved a roller pump and heat exchanger, with cisplatin added at 40.8°C.
- Surgical procedures varied, including extrapleural pneumonectomy and tumor resection.
Main Results:
- No technical issues during perfusion; systemic temperature remained below 38°C.
- One case of thrombocytopenia was the only significant toxicity.
- Survival rates at 1, 2, and 3 years were 72%, 65%, and 44%, respectively.
Conclusions:
- Intraoperative HPP with cisplatin is feasible, safe, and technically straightforward.
- This approach demonstrates potential for excellent local control in pleural tumors.
- The multimodality treatment shows promising early results for pleural malignancies.